Product Details

Uniprot No.

Target Names

Alternative Names

Tyrosine-protein kinase BTK (EC 2.7.10.2) (Agammaglobulinemia tyrosine kinase) (ATK) (B-cell progenitor kinase) (BPK) (Bruton tyrosine kinase), BTK, AGMX1 ATK BPK

Species Reactivity

Human

Immunogen

A synthesized peptide derived from human BTK

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

Rabbit IgG

Clone No.

3E5

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.

Form

Liquid

Tested Applications

ELISA, IHC

Recommended Dilution

Application	Recommended Dilution
IHC	1:50-1:200

Protocols

ELISA Protocol
Immunohistochemistry (IHC) Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Description

Bruton's tyrosine kinase (BTK) serves as a critical signaling hub in B-cell development and function, playing an essential role in B-cell receptor signaling pathways that govern proliferation, differentiation, and survival. Its significance extends beyond basic immunology research, as BTK has emerged as a therapeutic target in B-cell malignancies and autoimmune disorders, making reliable detection tools indispensable for both fundamental studies and translational research.

This recombinant monoclonal antibody, clone 3E5, offers the consistency and reproducibility that demanding research applications require. Generated against a synthetic peptide derived from human BTK and produced using recombinant technology in rabbit host, this antibody provides sequence-defined specificity with minimal lot-to-lot variation. The monoclonal nature ensures that every vial delivers identical binding characteristics, eliminating a common source of experimental variability that can complicate longitudinal studies or multi-site collaborations.

Validation in immunohistochemistry demonstrates robust performance in paraffin-embedded human tonsil tissue, a B-cell rich environment well-suited for confirming BTK detection. Using a Leica Bond system with citrate buffer antigen retrieval and HRP-polymer detection, clear staining was achieved at 1:100 dilution, with recommended working dilutions ranging from 1:50 to 1:200 depending on tissue type and detection system sensitivity. The antibody is also validated for ELISA applications, providing flexibility across different experimental workflows.

Supplied in a stabilized liquid format with glycerol for convenient long-term storage at -20°C or -80°C, this affinity-purified antibody is ready to support investigations into B-cell biology, immune signaling cascades, and related therapeutic development programs.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Related Products

Target Background

Function

Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation. After BCR engagement and activation at the plasma membrane, phosphorylates PLCG2 at several sites, igniting the downstream signaling pathway through calcium mobilization, followed by activation of the protein kinase C (PKC) family members. PLCG2 phosphorylation is performed in close cooperation with the adapter protein B-cell linker protein BLNK. BTK acts as a platform to bring together a diverse array of signaling proteins and is implicated in cytokine receptor signaling pathways. Plays an important role in the function of immune cells of innate as well as adaptive immunity, as a component of the Toll-like receptors (TLR) pathway. The TLR pathway acts as a primary surveillance system for the detection of pathogens and are crucial to the activation of host defense. Especially, is a critical molecule in regulating TLR9 activation in splenic B-cells. Within the TLR pathway, induces tyrosine phosphorylation of TIRAP which leads to TIRAP degradation. BTK plays also a critical role in transcription regulation. Induces the activity of NF-kappa-B, which is involved in regulating the expression of hundreds of genes. BTK is involved on the signaling pathway linking TLR8 and TLR9 to NF-kappa-B. Transiently phosphorylates transcription factor GTF2I on tyrosine residues in response to BCR. GTF2I then translocates to the nucleus to bind regulatory enhancer elements to modulate gene expression. ARID3A and NFAT are other transcriptional target of BTK. BTK is required for the formation of functional ARID3A DNA-binding complexes. There is however no evidence that BTK itself binds directly to DNA. BTK has a dual role in the regulation of apoptosis.

Gene References into Functions

Btk acts in the TLR7/8 pathway and mediates Ser-536 phosphorylation of p65 RelA and subsequent nuclear entry in primary human macrophages. PMID: 29567473
Study shows that high BTK expression predicts poor outcome in patients with glioma. Its overexpression is required for EGFR-induced NF-kappaB activation. PMID: 28946903
The Btk-dependent PIP5K1gamma lipid kinase activation by Fas counteracts FasL-induced cell death. PMID: 28879546
Study utilized bone biopsies from patients with metastatic multiple myeloma and demonstrated that tyrosine phosphorylation by Bruton kinase may be a key disease event: Bruton kinase remained translocated to the membrane; upregulation of transcripts of several factors like activins A; increased expression of numerous cytokines that support osteolytic activity. PMID: 29480835
BTK-inhibitor ibrutinib and FK866 resulted in a significant and synergistic anti-Waldenstrom macroglobulinemia cell death, regardless of MYD88 and CXCR4 mutational status. PMID: 27287071
Strong synergism was observed with pimasertib combined with the PI3K inhibitor idelalisib and the BTK inhibitor ibrutinib in cell lines derived from diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma. The data were confirmed in an in vivo experiment treating DLBCL xenografts with pimasertib and ibrutinib. PMID: 26961147
these data show that BTK is a critical NLRP3 inflammasome regulator PMID: 28216434
Resistant BTK mutants reconstituted B cell receptor-triggered chemokine secretion in the presence of corresponding inhibitors, demonstrating that BTK activity is connected with cell-intrinsic functions of malignant B cells with importance for their dialogue with the micro-environment. PMID: 28573668
Bone marrow mesenchymal stem cells could increase myeloma stemness via activation of the BTK signal pathway. PMID: 28273548
the results show that the interaction between BTK and ANKRD54 is highly selective, since it was also identified in a screen using human SH3-domainome. A novel finding is that BTK not only binds to ANKRD54, but stands out as the preferred interactor, being highly dominant over all other human SH3-domains. PMID: 28369144
BTK, via p65BTK expression, is a novel and powerful oncogene acting downstream of the RAS/MAPK pathway and suggest that its targeting may be a promising therapeutic approach. PMID: 26804170
We conclude that despite being involved in oncogenic signals in blood malignancies, BTK has antineoplastic properties in other contexts, such as the enhancement of p53's tumor suppressor responses PMID: 27630139
Inhibition of Btk by inhalation of aerosolized RN983 may be effective as a stand-alone asthma therapy. PMID: 27111445
LMP2A signaling results in STAT3 phosphorylation in B cells through a PI3K/BTK-dependent pathway. PMID: 27792904
Case Report: Btk mutation responsible for X-Linked agammaglobulinemia manifesting as Pseudomonas aeruginosa liver abscess. PMID: 28398200
this review describes contributions of BTK to immune tolerance, including studies testing BTK-inhibitors for treatment of autoimmune diseases PMID: 26864273
The lack of BTK does not impair monocytes and polymorphonuclear cells functions in X-linked agammaglobulinemia under treatment with intravenous immunoglobulin. PMID: 28422989
report that BTK is expressed by murine and human MDSCs, and that ibrutinib is able to inhibit BTK phosphorylation in these cells PMID: 26880800
Novel BTK mutations have been described in a large cohort of North African patients with X-Linked agammagobulinemia. PMID: 26931785
mutational analysis in cohort of Iranian patients with congenital agammaglobulinemia PMID: 26910880
We report that BTK regulates B-cell and macrophage-mediated T-cell suppression in pancreas adenocarcinomas. PMID: 26715645
Data show that Bruton tyrosine kinase (BTK)inhibitor Ibrutinib augments MALT lymphoma associated translocation protein (MALT1) inhibition by S-Mepazine in CD79 antigen mutant activated B cell-subtype (ABC) of diffuse large B cell lymphoma (DLBCL). PMID: 26540570
BTK-C is a survival factor in prostate cancer cells. PMID: 26383180
BTK RNA interference inhibits proliferation of FLT3-ITD acute myeloid leukemia cells. PMID: 26292723
Activates PKC independent of BTK. PMID: 26089373
study investigated all single-nucleotide substitution-caused amino acid variations in the kinase domain of Bruton tyrosine kinase; most disease-causing variations affect conserved and buried residues disturbing protein stability; sixty-seven percent of variations are predicted to be harmful PMID: 25777788
Data show that Bruton tyrosine kinase (Btk) inhibitor PLS-123 suggested a new direction to pharmacologically modulate Btk function and develop novel therapeutic drug for B-cell lymphoma treatment. PMID: 25944695
FcgammaRIIB requires Btk and p38 MAPK to mediate antigen-independent inhibition in human B cells. PMID: 26475492
We found that chemoresistance was dependent on Btk and JAK2/STAT3, which maintained CSC by inducing Sox-2 and prosurvival genes. We suggest that addition of ibrutinib to cisplatin may improve treatment outcome in ovarian cancer. PMID: 26036311
Letter: report BTK inhibitor ibrutinib induced panniculitis in lymphoid leukemia patients. PMID: 26182170
study indicates that BTK is essential for NLRP3 inflammasome activation and could be a potent therapeutic target in ischaemic stroke PMID: 26059659
Data indicate that the X linked agammaglobulinemia (XLA) diagnosis was confirmed for six patients with six different mutations. PMID: 26387629
The immunoglobulin tail tyrosine motif in the cytoplasmic segments of membrane-bound IgGs acts as the principle signal amplifier by incorporating a Grb2-Btk signaling. PMID: 25413232
Btk not only plays a fundamental role in the regulation of BCR signalling, but may also mediate crosstalk with cytokine signalling pathways through regulation of IL-21-induced phosphorylation of STAT1 in the nuclei of human B cells. PMID: 25724205
The BTK missense mutation resulted in B cells with reduced BTK and high IgM expression. PMID: 25589397
BTK is involved in determining proliferative, quiescent or metastatic phenotypes of myeloma cells. PMID: 25083818
report of a case in a male with variant form of X-linked agammaglobulinemia (XLA) with partial B cell function that results from a missense mutation (c.1117C > G) in exon 13 of the BTK gene; four female carriers were found in the family PMID: 25316352
miR-155 affects chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib PMID: 25486872
BTK is a positive regulator of myeloma stemness PMID: 25589346
Cysteine 481 to serine BTK mutation confers ibrutinib resistance of chronic lymphocytic leukemia cells. PMID: 25189416
FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation PMID: 25605370
Data indicate that dual inhibition of Brutons tyrosine kinase (BTK) and mTOR serine-threonine kinases as a potential treatment for ABC-subtype diffuse large B cell lymphoma. PMID: 24970801
Docking and physicochemical studies indicated that BTK was involved in close contact with Tyr86 and Tyr106 of MAL, whereas PKCdelta may phosphorylate Tyr106 only. PMID: 24840642
X-linked agammaglobulinemia is reported in two siblings with a novel mutation in the BTK gene. They presented with polyarticular juvenile idiopathic arthritis. PMID: 25757060
Data indicate RN486 as potent and selective Bruton's tyrosine kinase (BTK) inhibitor and potential treatments for Rheumatoid arthritis. PMID: 24712864
we report the pattern of expression of Btk in a large collection of different types of lymphoma. PMID: 25433814
Data indicate that ibrutinib-resistant Bruton tyrosine kinase (BTK) mutation is one of the genetic causes of ibrutinib resistance in chronic lymphocytic leukemia (CLL). PMID: 25498455
Unfolded protein response activation following surface immunoglobulin M stimulation in vitro is dependent on the activity of BTK and SYK. PMID: 25170122
We observed that Nef interacts with the Tec family members Bmx, Btk, and Itk but not Tec or Txk. PMID: 24722985
These results suggest that the function of BTK warrants further investigation, and BTK expression might be used as a prognostic indicator for patients with MM. PMID: 23581641

Hide All

Involvement in disease

X-linked agammaglobulinemia (XLA); X-linked hypogammaglobulinemia and isolated growth hormone deficiency (XLA-IGHD)

Subcellular Location

Cytoplasm. Cell membrane; Peripheral membrane protein. Nucleus. Note=In steady state, BTK is predominantly cytosolic. Following B-cell receptor (BCR) engagement by antigen, translocates to the plasma membrane through its PH domain. Plasma membrane localization is a critical step in the activation of BTK. A fraction of BTK also shuttles between the nucleus and the cytoplasm, and nuclear export is mediated by the nuclear export receptor CRM1.

Protein Families

Protein kinase superfamily, Tyr protein kinase family, TEC subfamily

Tissue Specificity

Predominantly expressed in B-lymphocytes.

Database Links

HGNC: 1133

OMIM: 300300

KEGG: hsa:695

STRING: 9606.ENSP00000308176

UniGene: Hs.159494

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Code	CSB-RA553167A0HU
Size	US$210
	Order now
Image	IHC image of CSB-RA553167A0HU diluted at 1:100 and staining in paraffin-embedded human tonsil tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.
Have Questions?	Leave a Message or Start an on-line Chat

BTK Recombinant Monoclonal Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background